Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program

Category Primary study
JournalEndocrine Reviews
Year 2016
This article has no abstract
Epistemonikos ID: 90dc605f96451d62fad6e6d01ad7f20e4feb8bec
First added on: Feb 08, 2025